Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases
NCT03320538 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360
Last updated 2024-07-03
Summary
This trial aims to determine whether Jiangzhong Hou Gu® Mi Xi™ is an effective intervention to improve symptoms and indicators in patients with spleen qi deficiency and peptic ulcer diseases.
Conditions
- Peptic Ulcer Disease
Interventions
- OTHER
-
Hou Gu Mi Xi
Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
- OTHER
-
Placebo
The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
- DRUG
-
Rabeprazole
Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
Sponsors & Collaborators
-
Jiangxi Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
The First Affiliated Hospital of Nanchang University
collaborator OTHER -
Second Affiliated Hospital of Nanchang University
collaborator OTHER -
The Third Affiliated Hospital of Nanchang University
collaborator OTHER -
Nanchang Hongdu Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
Nanchang Hospital of Integrated Traditional Chinese and Western Medicine
collaborator UNKNOWN -
The Nanchang Third Hospital
collaborator UNKNOWN -
Xinyu People's Hospital
collaborator UNKNOWN -
Xinyu Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
Jiujiang No.1 People's Hospital
collaborator OTHER -
Jiujiang Hospital of Traditional Chinese Medicine
collaborator UNKNOWN -
Jiangxi University of Traditional Chinese Medicine
lead OTHER
Principal Investigators
-
Weifeng Zhu, Ph.D. · Jiangxi University of Traditional Chinese Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-10
- Primary Completion
- 2020-09-17
- Completion
- 2020-09-17
Countries
- China
Study Locations
More Related Trials
-
Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease
NCT02892357 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
NCT05930119 ·Status: COMPLETED ·Phase: PHASE1
-
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT03362281 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Jianpi Qinghua Granules in Patients With Nonerosive Reflux Disease
NCT04324138 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis
NCT01284647 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
NCT01190657 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong Province
NCT00339768 ·Status: COMPLETED ·Phase: PHASE3
-
IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT03362268 ·Status: COMPLETED ·Phase: PHASE2
-
XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)
NCT06055179 ·Status: RECRUITING ·Phase: NA
-
A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
NCT04503629 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
NCT02658864 ·Status: COMPLETED ·Phase: PHASE1
-
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
NCT00125736 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study
NCT00517270 ·Status: UNKNOWN ·Phase: NA
-
Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG
NCT03908593 ·Status: UNKNOWN ·Phase: PHASE4
-
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
NCT03038009 ·Status: WITHDRAWN ·Phase: PHASE4
-
Importance of Cytokines in Peptic Ulcer Disease: Implications for Treatment
NCT00534443 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
NCT07284173 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
NCT05010954 ·Status: COMPLETED ·Phase: PHASE3
-
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
NCT00953381 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
NCT00401752 ·Status: COMPLETED ·Phase: PHASE3
-
Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication
NCT06168214 ·Status: RECRUITING ·Phase: PHASE4
-
The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets
NCT06337604 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of Tegoprazan on Healthy Male Volunteers
NCT03530228 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
NCT02097329 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Selective COX-2 Inhibition on Ulcer Healing
NCT00153673 ·Status: COMPLETED ·Phase: PHASE3